注射吸毒者丙肝治疗:初级保健与医院专科随机对照试验
该随机对照试验将澳大利亚和新西兰初级保健机构的注射吸毒丙肝患者分配至初级保健点或当地医院接受直接抗病毒药物(DAA)治疗。初级保健组SVR12率100%(95%CI 87.7-100)非劣于历史对照(假定85%)。意向性分析显示初级保健组治疗启动比例(75%,43/57)显著高于标准护理组(34%,18/53;P<.001;RR 2.48,95%CI 1.54-3.95),SVR12比例亦显著更高(49% [28/57] vs 30% [16/53];P=.043;RR 1.63,95%CI 1.0-2.65)。
要点
- 初级保健点提供DAA治疗可显著提高注射吸毒者的治疗启动率
- 初级保健组SVR12率非劣于历史对照,支持其有效性
- 在初级保健中治疗丙肝有助于加速消除目标
核心结论
- 在初级保健中提供HCV治疗可提高注射吸毒者的治疗启动率和治愈率。
- 增加注射吸毒者治疗可及性的策略将加速消除策略。
研究设计与样本
- 随机对照试验,在澳大利亚和新西兰的初级保健机构招募注射吸毒的HCV患者。
- 共招募140例,随机136例:初级保健组70例,标准护理组66例。
- 主要结局为初级保健组治疗者SVR12率非劣于历史对照(假定85%)。
主要发现
- 初级保健组SVR12率100%(95%CI 87.7-100),非劣于历史对照。
- 意向性分析中,初级保健组治疗启动比例75%(43/57)显著高于标准护理组34%(18/53),P<.001,RR 2.48(95%CI 1.54-3.95)。
- 初级保健组SVR12比例49%(28/57)显著高于标准护理组30%(16/53),P=.043,RR 1.63(95%CI 1.0-2.65)。
关键数值与推荐
- 主要结局非劣效界值未在摘要中报告。
- 历史对照假定SVR12率为85%。
临床怎么用
- 可在初级保健机构为注射吸毒的HCV患者提供DAA治疗以提高治疗启动率。
- 初级保健治疗可获得高SVR12率,支持扩大治疗可及性。
局限性
- 主要结局采用历史对照比较,非同期对照。
- 摘要未报告非劣效界值及其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to direct-acting antivirals (DAAs), especially among people who inject drugs (PWID). We aimed to determine the effectiveness of providing DAAs in primary care, compared with hospital-based specialist care. METHODS: We randomized PWID with HCV attending primary care sites in Australia or New Zealand to receive DAAs at their primary care site or local hospital (standard of care [SOC]). The primary outcome was to determine whether people treated in primary care had a noninferior rate of sustained virologic response at Week 12 (SVR12), compared to historical controls (consistent with DAA trials at the time of the study design); secondary outcomes included comparisons of treatment initiation, SVR12 rates, and the care cascade by study arm. RESULTS: We recruited 140 participants and randomized 136: 70 to the primary care arm and 66 to the SOC arm. The SVR12 rate (100%, 95% confidence interval [CI] 87.7-100) of people treated in primary care was noninferior when compared to historical controls (85% assumed). An intention-to-treat analysis revealed that the proportion of participants commencing treatment in the primary care arm (75%, 43/57) was significantly higher than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), and the proportion of participants with SVR12 was significantly higher in the primary care arm, compared to in the SOC arm (49% [28/57] and 30% [16/53], respectively; P = .043; RR 1.63, 95% CI 1.0-2.65). CONCLUSIONS: Providing HCV treatment in primary care increases treatment uptake and cure rates. Approaches that increase treatment uptake among PWID will accelerate elimination strategies. CLINICAL TRIALS REGISTRATION: NCT02555475.
引用
- Wade AJ, Doyle JS, Gane E, et al. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clin Infect Dis. 2020. PMID: 31233117. doi:10.1093/cid/ciz546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。